PT-141 (Bremelanotide): Evidence Before Hype
Bremelanotide (PT-141) is a melanocortin receptor agonist with a distinctive role in sexual-medicine research. Unlike therapies that primarily act through peripheral vascular mechanisms, bremelanotide acts centrally through melanocortin pathways involved in sexual desire and arousal.
The Founder’s Institute of Medicine & Education PT-141 Peptide Intelligence Monograph examines the clinical evidence behind its FDA-approved use while carefully separating established findings from broader claims surrounding sexual function, erectile dysfunction, performance enhancement, and off-label use.
Inside the monograph:
• Compound identity and melanocortin pharmacology
• MC4R and central nervous system mechanisms
• FDA-approved bremelanotide (Vyleesi®) indication
• Acquired, generalized HSDD in premenopausal women
• RECONNECT Phase 3 clinical evidence
• Sexual desire, arousal, and distress outcomes
• Male erectile-dysfunction research and its limitations
• Desire versus peripheral sexual-performance mechanisms
• Cardiovascular and blood-pressure considerations
• Nausea, hyperpigmentation, and other adverse effects
• Drug interactions and important precautions
• Approved-product versus research-market distinctions
• Claim-by-claim FIPES evidence assessment
• Fully referenced scientific literature
Institute Bottom Line: Bremelanotide has established human clinical evidence and an FDA-approved indication for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That evidence should not be extrapolated into universal claims regarding libido, erectile dysfunction, sexual performance, or use in populations for which efficacy and safety have not been established.
Version 1.0 | Evidence cutoff: August 25, 2026
Educational scientific evidence review. Not medical advice, a treatment protocol, prescription, or promotional claim.
This publication is provided solely for educational and informational purposes. It does not constitute medical advice, diagnosis, prescribing guidance, or a recommendation for individual treatment. It is not intended to replace evaluation, consultation, or treatment by a qualified healthcare professional. Treatment decisions must be based on the individual patient's circumstances and made in consultation with an appropriately licesnsed healthcare professional.